Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
ESSA Pharma Inc (EPIX)
NASDAQ:EPIX
Holding EPIX?
Track your performance easily
EPIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.63 - $11.67
Previous Close$6.77
Volume102.44K
Average Volume (3M)52.01K
Market Cap
$275.97M
Enterprise Value$170.03M
Total Cash (Recent Filing)$130.69M
Total Debt (Recent Filing)$342.14K
Price to Earnings (P/E)―
Beta2.74
Next Earnings
Dec 10, 2024EPS Estimate
-$0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.63
Shares Outstanding44,368,959
10 Day Avg. Volume62,008
30 Day Avg. Volume52,013
Standard Deviation0.27
R-Squared0.13
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)2.33
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.22
Forecast
1Y Price Target
$16.67Price Target Upside168.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
ESSA Pharma News
PremiumCompany Announcements
ESSA Pharma Advances Prostate Cancer Clinical Trials
PremiumCompany Announcements
ESSA Pharma’s Promising Prostate Cancer Trial Updates
PremiumCompany Announcements
ESSA Pharma Shareholders Show Strong SupportBulls Say, Bears Say
Bulls Say
Clinical TrialsMedian time to PSA progression and radiographic progression-free survival were not reached, comparing favorably with peer clinical trial outcomes.
Data ReadoutsEssa has multiple shots on goal with several data readouts in the next 12 months across different stages in prostate cancer.
Strategy ValidationPeers' presentations at ASCO support Essa's strategy in prostate cancer by targeting earlier stages of disease in clinically relevant patient populations.
Bears Say
Clinical TrialsTwo presentations in 1L mCRPC showed no survival benefit with the tested treatment, Lilly's Phase 3 CYCLONE 2 trial and ECOG-ACRIN's Phase 2 CHAARTED 2 trial.
Investor SentimentStock came under pressure following Essa's ASCO GU data, as investors were comparing the low baseline PSA levels to other older studies.
Market ConditionsPoor market conditions can push the stock back to its August lows of ~$4.50 irrespective of the data.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EPIX FAQ
What was ESSA Pharma Inc’s price range in the past 12 months?
ESSA Pharma Inc lowest stock price was $2.63 and its highest was $11.67 in the past 12 months.
What is ESSA Pharma Inc’s market cap?
Currently, no data Available
When is ESSA Pharma Inc’s upcoming earnings report date?
ESSA Pharma Inc’s upcoming earnings report date is Dec 10, 2024 which is in 82 days.
How were ESSA Pharma Inc’s earnings last quarter?
ESSA Pharma Inc released its earnings results on Aug 05, 2024. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.246 by $0.086.
Is ESSA Pharma Inc overvalued?
According to Wall Street analysts ESSA Pharma Inc’s price is currently Undervalued.
Does ESSA Pharma Inc pay dividends?
ESSA Pharma Inc does not currently pay dividends.
What is ESSA Pharma Inc’s EPS estimate?
ESSA Pharma Inc’s EPS estimate is -$0.2.
How many shares outstanding does ESSA Pharma Inc have?
ESSA Pharma Inc has 44,368,958 shares outstanding.
What happened to ESSA Pharma Inc’s price movement after its last earnings report?
ESSA Pharma Inc reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.246. Following the earnings report the stock price went down -1.907%.
Which hedge fund is a major shareholder of ESSA Pharma Inc?
Among the largest hedge funds holding ESSA Pharma Inc’s share is EntryPoint Capital, LLC. It holds ESSA Pharma Inc’s shares valued at N/A.
---
ESSA Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.67 (168.01% Upside)
$16.67 (168.01% Upside)
Blogger Sentiment
Bullish
EPIX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 4.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.5%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
155.47%
12-Months-Change
Fundamentals
Return on Equity
-19.83%
Trailing 12-Months
Asset Growth
-13.66%
Trailing 12-Months
Company Description
ESSA Pharma Inc
ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
---
EPIX Stock 12 Month Forecast
Average Price Target
$16.67
▲(168.01% Upside)
Technical Analysis
Karyopharm Therapeutics
―
TRACON Pharmaceuticals
―
Cyclerion Therapeutics
―
Oncternal Therapeutics
―
Best Analysts Covering EPIX
1 Year
1 Year Success Rate
5/7 ratings generated profit
1 Year Average Return
+38.77%
reiterated a buy rating 3 days ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +38.77% per trade.
---